Journal: PloS one

Article Title: Docosahexaenoic Acid Inhibits Tumor Promoter-Induced Urokinase-Type Plasminogen Activator Receptor by Suppressing PKC?- and MAPKs-Mediated Pathways in ECV304 Human Endothelial Cells.

PMID/MRN: 27654969

Publication Date: 2016-10-17

Abstract:

The overexpression of urokinase-type plasminogen activator receptor (uPAR) is associated with inflammation and virtually all human cancers. Despite the fact that docosahexaenoic acid (DHA) has been reported to possess anti-inflammatory and anti-tumor properties, the negative regulation of uPAR by DHA is still undefined. Here, we investigated the effect of DHA on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced uPAR expression and the underlying molecular mechanisms in ECV304 human endothelial cells. DHA concentration-dependently inhibited TPA-induced uPAR. Specific inhibitors and mutagenesis studies showed that PKC?, JNK1/2, Erk1/2, NF-?B, and AP-1 were critical for TPA-induced uPAR expression. Application of DHA suppressed TPA-induced translocation of PKC?, activation of the JNK1/2 and Erk1/2 signaling pathways, and subsequent AP-1 and NF-?B transactivation. In conclusion, these observations suggest a novel role for DHA in reducing uPAR expression and cell invasion by inhibition of PKC?, JNK1/2, and Erk1/2, and the reduction of AP-1 and NF-?B activation in ECV304 human endothelial cells.